According to our new research study on "Health Economics and Outcome Research (HEOR) Services Market Forecast to 2031 - Global Analysis - by Service, Service Provider, and End User," the market is expected to grow from US$ 1,682.92 million in 2024 to US$ 3,797.86 million by 2031; it is estimated to record a CAGR of 12.3% from 2024-2031. Key factors driving the growth of health economics and outcome research (HEOR) services market are increasing product development, growing healthcare spending, and a surge in clinical trials. However, restrictions on access to real-world data hinder the market's growth.

The scope of the health economics and outcome research (HEOR) services market report includes the assessment of the market performance in North America, Europe, Asia Pacific, South & Central America, and the Middle East & Africa. Asia Pacific is anticipated to register the fastest CAGR in the health economics and outcome research (HEOR) services market from 2024 to 2031. Owing to the growing emphasis on cost optimization, focus on streamlining clinical processes, supportive government policies, and the increasing number of clinical trials, the market is expected to witness growth in the region. Additionally, the rapid economic growth in countries like China and India has led to improvements in healthcare infrastructure and greater access to advanced medical treatments, supporting the growth of the health economics and outcome research (HEOR) services market growth in Asia Pacific. As the region experiences an aging population, which contributes to the growing prevalence of chronic diseases, there is an increasing burden on healthcare systems. As a result, healthcare providers and pharmaceutical companies are increasingly seeking to demonstrate the value of new treatments through HEOR studies. Moreover, the rising penetration of global pharmaceutical companies into the region has led to a surge in demand for market access and reimbursement strategies, where HEOR plays a crucial role.

China, India, and Japan are three significant contributors to the market growth in this region. China has a vast population and has flourished healthcare infrastructure, with rapid growth in communication. The government in China is actively engaged in providing advanced solutions to improve the quality of healthcare. In addition, increasing investments in drug discovery as well as healthcare optimizations are likely to contribute to the growth of China's health economic and outcomes research services market during the forecast period. In September 2020, Pfizer announced its proposed plan to invest US$ 200 million in China-based biotechnology company CStone Pharmaceuticals. The collaboration is planning to develop cancer therapeutics. Such collaborations are estimated to drive the demand for HEOR solutions in the country.

Academic institutes and research centers are also emphasizing the adoption of HEOR services in order to make data-driven strategic decisions. In February 2021, the collaboration between the Analysis Group and the Institute of Hematology & Blood Diseases Hospital, a clinical research center of the Chinese Academy of Medical Sciences, and Peking Union Medical College announced positive results of their studies regarding hemophilia in China. The research institute is utilizing real-world evidence solutions provided by Analysis Group to make data-driven decisions. Further, the government of China is actively investing and prioritizing the use of HEOR solutions to validate the product market access. For instance, in April 2020, Allergan plc received approval for its XEN gel stent from China's National Medical Products Administration. The approving authority used real world evidence solutions in order to validate the product applications, aiding the health economics and outcome research (HEOR) services market growth.

Moreover, increasing patient population along with rising utilization and access to healthcare, the management of resources in healthcare becomes a crucial part. Japan has a compulsory health insurance system that provides universal coverage financed by taxes and individual contributions. HEOR services are used to assess the cost-effectiveness of treatments within this system, ensuring the high quality and affordability of healthcare.

HEOR in Japan uses real-world data to assess the value of medical products and services. This helps pharmaceutical companies and healthcare providers demonstrate the economic and clinical benefits of their offerings. For instance, the use of RWD (e.g., the SCRUM-Japan registry) as a source of external control data in the regulatory review of the label expansion of pertuzumab and trastuzumab in patients with HER2-positive advanced/recurrent unresectable colorectal cancer in March 2022. Additionally, in March 2020, TriNetX, an international healthcare research network, announced a strategic partnership with Japan-based Medical Data Vision. The company partnership is expected to offer clinical research as well as real-world data solutions in Japan, favoring the health economics and outcome research (HEOR) services market growth.

Furthermore, the adoption of Health Economic and Outcomes Research (HEOR) services in India is gradually evolving, driven by the growing demand for cost-effective healthcare solutions and the need for evidence-based decision-making in the healthcare sector. In February 2022, Jehangir Clinical Development Center (JCDC) announced a collaboration with Actu-Real for further research. This collaboration is aimed to focus on the collection and analysis of real-world data generated from clinical practice to support evidence-based clinical, economic, and regulatory decisions.

Awareness and understanding of HEOR in India remains limited compared to more developed markets despite this promising trajectory. Currently, HEOR services are essential to support drug approval processes, where pharmaceutical companies must demonstrate the cost-effectiveness of their products compared to existing therapies. However, the concept of health technology assessment (HTA) is not yet well established in India, which hinders the full potential of HEOR services. Companies such as Heorlytics are stepping in to fill this gap by providing expertise in health economic modeling and evidence synthesis to help Indian companies adapt to global HTA requirements.

The international market players are emphasizing the expansion of their customer base in India. For instance, in April 2020, Axtria announced the expansion of its delivery center in Bengaluru, India. The new center is especially dedicated to big data analytics and the development of cloud software in order to meet the extensively increasing demand for healthcare analytics and information services. The factors mentioned above are promoting a favorable environment for the market in the region.

PharmaLex GmbH; ICON Plc; IQVIA Holdings Inc.; Syneos Health Inc.; Optum Inc.; Certara Inc.; ExlService Holdings, Inc.; Avalon Health Economics LLC; Axtria Inc.; and McKesson Corp are among the leading companies profiled in the health economics and outcome research (HEOR) services market report.

Based on service, the health economics and outcome research (HEOR) services market is categorized into economic modelling or evaluation, real world data analysis and information system, market access solutions and reimbursement, clinical outcome, and others. Based on service provider, the market is bifurcated into consultancy and contract research organizations. By end user, the health economics and outcome research (HEOR) services market is segmented into healthcare providers, healthcare payers, biotech/pharma companies, and government organizations. Geographically, the market is categorized into North America (US, Canada, and Mexico), Europe (France, Germany, UK, Spain, Italy, and Rest of Europe), Asia Pacific (China, Japan, India, South Korea, Australia, and Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, the UAE, and Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and Rest of South & Central America).

Contact Us
Phone: +1-646-491-9876
Email Id: sales@premiummarketinsights.com